SREBF1 and metabolic dysfunction-associated steatotic liver disease: The results of investigating the mechanism (Figure 7) showed that saroglitazar and curcumin treatment caused overexpression of PPARα in the NAFLD model, which is the upstream negative regulator of SREBP1.